SI1228039T1 - N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them - Google Patents
N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising themInfo
- Publication number
- SI1228039T1 SI1228039T1 SI200030422T SI200030422T SI1228039T1 SI 1228039 T1 SI1228039 T1 SI 1228039T1 SI 200030422 T SI200030422 T SI 200030422T SI 200030422 T SI200030422 T SI 200030422T SI 1228039 T1 SI1228039 T1 SI 1228039T1
- Authority
- SI
- Slovenia
- Prior art keywords
- guanidinoalkylamides
- preparation
- pharmaceutical preparations
- preparations
- pharmaceutical
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99121623A EP1095933A1 (en) | 1999-10-30 | 1999-10-30 | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| EP00971396A EP1228039B1 (en) | 1999-10-30 | 2000-10-21 | N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| PCT/EP2000/010395 WO2001032611A1 (en) | 1999-10-30 | 2000-10-21 | N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1228039T1 true SI1228039T1 (en) | 2004-10-31 |
Family
ID=8239305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200030422T SI1228039T1 (en) | 1999-10-30 | 2000-10-21 | N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US6472562B1 (enExample) |
| EP (2) | EP1095933A1 (enExample) |
| JP (1) | JP4658430B2 (enExample) |
| KR (1) | KR100981593B1 (enExample) |
| CN (1) | CN1249026C (enExample) |
| AR (1) | AR026257A1 (enExample) |
| AT (1) | ATE264837T1 (enExample) |
| AU (1) | AU776797B2 (enExample) |
| BR (1) | BR0015186A (enExample) |
| CA (1) | CA2389412C (enExample) |
| CZ (1) | CZ301855B6 (enExample) |
| DE (1) | DE60010113T2 (enExample) |
| DK (1) | DK1228039T3 (enExample) |
| EE (1) | EE05168B1 (enExample) |
| ES (1) | ES2220553T3 (enExample) |
| HR (1) | HRP20020372B1 (enExample) |
| HU (1) | HUP0203627A3 (enExample) |
| IL (2) | IL149209A0 (enExample) |
| ME (1) | MEP54708A (enExample) |
| MX (1) | MXPA02003805A (enExample) |
| NO (1) | NO328016B1 (enExample) |
| NZ (1) | NZ518607A (enExample) |
| PL (1) | PL203859B1 (enExample) |
| PT (1) | PT1228039E (enExample) |
| RS (1) | RS50471B (enExample) |
| RU (1) | RU2253651C2 (enExample) |
| SI (1) | SI1228039T1 (enExample) |
| SK (1) | SK286856B6 (enExample) |
| TR (1) | TR200201181T2 (enExample) |
| WO (1) | WO2001032611A1 (enExample) |
| ZA (1) | ZA200203294B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1644401E (pt) * | 2003-07-04 | 2011-06-06 | Lonza Ag | Acesso melhorado para síntese em fase suportada |
| KR102069498B1 (ko) | 2007-09-28 | 2020-01-23 | 포톨라 파마슈티컬스, 인코포레이티드 | 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법 |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| BRPI0906473A8 (pt) | 2008-01-04 | 2016-02-10 | Intellikine Inc | Certas entidades químicas, composições e métodos |
| RU2377990C1 (ru) * | 2008-07-23 | 2010-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов |
| CA2743496C (en) | 2008-11-14 | 2018-03-27 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
| PL3604510T3 (pl) | 2009-03-30 | 2025-07-28 | Alexion Pharmaceuticals, Inc. | Antidota na inhibitory czynnika xa i sposoby ich stosowania |
| EP2453910B1 (en) | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
| EP3238722B1 (en) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN110357800B (zh) * | 2018-04-09 | 2022-07-26 | 青岛海生洋润生物科技有限公司 | 脯氨酸衍生物及其在制备治疗心脑血管疾病药物中的应用 |
| CN121221582A (zh) * | 2021-05-10 | 2025-12-30 | 中国海洋大学 | 一种苯酰胍衍生物在用于制备预防和治疗神经系统疾病或心血管系统疾病的药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU206372B (en) * | 1990-09-03 | 1992-10-28 | Richter Gedeon Vegyeszet | Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5371072A (en) * | 1992-10-16 | 1994-12-06 | Corvas International, Inc. | Asp-Pro-Arg α-keto-amide enzyme inhibitors |
| DE4326465A1 (de) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| WO1994017635A1 (en) | 1993-01-20 | 1994-08-04 | Peter John Alexandrovics | A line monitoring system |
| NZ263084A (en) * | 1993-03-12 | 1997-08-22 | Arris Pharm Corp | Dipeptide derivatives, treatment of immunomediated inflammatory disorders |
| ZA953361B (en) | 1994-04-26 | 1996-01-12 | Selectide Corp | Factor Xa inhibitors |
| NZ296210A (en) * | 1994-12-02 | 1998-05-27 | Yamanouchi Pharma Co Ltd | Amidinonaphthyl derivatives to inhibit activated blood coagulation factor x |
| US6342504B1 (en) * | 1994-12-13 | 2002-01-29 | Corvas International, Inc. | Aromatic heterocyclic derivatives as enzyme inhibitors |
| EP1020434A4 (en) * | 1997-08-27 | 2000-11-15 | Kissei Pharmaceutical | 3-AMIDINOANILINE DERIVATIVES, INHIBITORS OF THE ACTIVATED BLOOD COINTENANCE FACTOR X AND INTERMEDIATE PRODUCTS FOR PRODUCING BOTH |
| SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
| BR9814340B1 (pt) | 1997-12-24 | 2010-07-13 | compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica. | |
| WO1999037643A1 (en) * | 1998-01-26 | 1999-07-29 | Yamanouchi Pharmaceutical Co., Ltd. | Novel benzene-fused heterocyclic derivatives or salts thereof |
| EP0987274A1 (en) | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
| US6348482B1 (en) * | 1999-05-05 | 2002-02-19 | Merck & Co., Inc. | Catechols as antimicrobial agents |
-
1999
- 1999-10-30 EP EP99121623A patent/EP1095933A1/en not_active Withdrawn
-
2000
- 2000-10-21 SK SK578-2002A patent/SK286856B6/sk not_active IP Right Cessation
- 2000-10-21 CZ CZ20021489A patent/CZ301855B6/cs not_active IP Right Cessation
- 2000-10-21 NZ NZ518607A patent/NZ518607A/en not_active IP Right Cessation
- 2000-10-21 ES ES00971396T patent/ES2220553T3/es not_active Expired - Lifetime
- 2000-10-21 DK DK00971396T patent/DK1228039T3/da active
- 2000-10-21 CA CA002389412A patent/CA2389412C/en not_active Expired - Fee Related
- 2000-10-21 ME MEP-547/08A patent/MEP54708A/xx unknown
- 2000-10-21 RU RU2002114041/04A patent/RU2253651C2/ru not_active IP Right Cessation
- 2000-10-21 HR HR20020372A patent/HRP20020372B1/xx not_active IP Right Cessation
- 2000-10-21 BR BR0015186-6A patent/BR0015186A/pt active Search and Examination
- 2000-10-21 CN CNB008151407A patent/CN1249026C/zh not_active Expired - Fee Related
- 2000-10-21 AU AU10265/01A patent/AU776797B2/en not_active Ceased
- 2000-10-21 KR KR1020027005515A patent/KR100981593B1/ko not_active Expired - Fee Related
- 2000-10-21 PT PT00971396T patent/PT1228039E/pt unknown
- 2000-10-21 AT AT00971396T patent/ATE264837T1/de active
- 2000-10-21 JP JP2001534764A patent/JP4658430B2/ja not_active Expired - Fee Related
- 2000-10-21 MX MXPA02003805A patent/MXPA02003805A/es active IP Right Grant
- 2000-10-21 WO PCT/EP2000/010395 patent/WO2001032611A1/en not_active Ceased
- 2000-10-21 IL IL14920900A patent/IL149209A0/xx active IP Right Grant
- 2000-10-21 EE EEP200200199A patent/EE05168B1/xx not_active IP Right Cessation
- 2000-10-21 PL PL354808A patent/PL203859B1/pl not_active IP Right Cessation
- 2000-10-21 TR TR2002/01181T patent/TR200201181T2/xx unknown
- 2000-10-21 RS YUP-297/02A patent/RS50471B/sr unknown
- 2000-10-21 DE DE60010113T patent/DE60010113T2/de not_active Expired - Lifetime
- 2000-10-21 SI SI200030422T patent/SI1228039T1/xx unknown
- 2000-10-21 EP EP00971396A patent/EP1228039B1/en not_active Expired - Lifetime
- 2000-10-21 HU HU0203627A patent/HUP0203627A3/hu unknown
- 2000-10-26 AR ARP000105647A patent/AR026257A1/es active IP Right Grant
- 2000-10-27 US US09/697,188 patent/US6472562B1/en not_active Expired - Lifetime
-
2002
- 2002-04-18 IL IL149209A patent/IL149209A/en not_active IP Right Cessation
- 2002-04-25 ZA ZA200203294A patent/ZA200203294B/xx unknown
- 2002-04-29 NO NO20022022A patent/NO328016B1/no not_active IP Right Cessation
- 2002-08-26 US US10/227,222 patent/US6664393B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0105414A3 (en) | Pyrrolo-isoquinoline, azepino- and diazepino-indole derivatives, their use and pharmaceutical compisitions containing them | |
| PL345539A1 (en) | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them | |
| HUP0103793A3 (en) | N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them | |
| AU5440901A (en) | Cosmetic and/or pharmaceutical preparations | |
| IL127132A (en) | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | |
| AU3957600A (en) | Piperidyl-imidazole derivatives, their preparations and therapeutic uses | |
| HUP0204081A3 (en) | 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use | |
| HRP20010655B1 (en) | Pyridopyranoazepine derivatives, preparation and therapeutic use | |
| EE05000B1 (et) | 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid | |
| HUP0202781A3 (en) | Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use | |
| HUP0203194A3 (en) | Phenylpiperazines, pharmaceutical compositions containing them and their use | |
| ZA200201057B (en) | Radiopharmaceutical products and their preparation procedure. | |
| HUP0203735A3 (en) | 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use | |
| IL149209A0 (en) | N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them | |
| SI1043307T1 (en) | 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use | |
| HUP0300334A3 (en) | Pharmaceutical preparations and their manufacture | |
| AU2438400A (en) | Cosmetic and/or pharmaceutical preparations | |
| AU4293800A (en) | Cosmetic and/or pharmaceutical preparations | |
| HUP0201810A3 (en) | Sootepenseone and its derivatives, their preparation and use as medicament | |
| PL351755A1 (en) | Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | |
| SI1043306T1 (en) | 3-amino-3-arylpropan-1-ol-derivates, their preparation and use | |
| HUP0203678A3 (en) | Nitro-sulfobenzamide-derivatives, preparation and use thereof | |
| IL132666A0 (en) | Phytoestrogenic pharmaceutical preparations | |
| IL146372A0 (en) | Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives, processes for their preparation, their use and pharmaceutical preparations comprising them | |
| HUP0203557A3 (en) | Novel amidine derivatives, preparation and use thereof as medicines |